Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 NOK | +0.36% | 0.00% | +15.23% |
Business Summary
Number of employees: 8
Sales per Business
NOK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Oncolytic Peptides
100.0
%
| 0 | nan % | 17 | 100.0 % | - |
Sales per region
NOK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
63.9
%
| - | - | 11 | 63.9 % | - |
Norway
36.1
%
| 0 | nan % | 6 | 36.1 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 07-12-31 | |
Gry Stensrud
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Ole Peter Nordby
IRC | Investor Relations Contact | - | - |
- | - | ||
Stephen Worsley
PRN | Corporate Officer/Principal | 60 | 22-09-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 21-06-06 |
Director/Board Member | 66 | 21-06-06 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 21-06-06 |
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Marie Roskrow
CHM | Chairman | - | 23-04-17 |
Evelina Vågesjö
BRD | Director/Board Member | 38 | 21-06-06 |
Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,578,121 | 29,872,541 ( 59.06 %) | 0 | 59.06 % |
Company contact information
Sector
Sales per region
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.23% | 20.64M | |
+21.57% | 46.81B | |
-1.07% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.33% | 26.06B | |
-19.33% | 19.13B | |
+32.16% | 12.39B | |
+0.09% | 12.08B | |
+0.17% | 11.96B |
- Stock Market
- Equities
- LYTIX Stock
- Company Lytix Biopharma